| 来源类型 | Working Paper |
| 规范类型 | 报告 |
| DOI | 10.3386/w11431 |
| 来源ID | Working Paper 11431 |
| Generic Scrip Share and the Price of Brand-Name Drugs: The Role of the Consumer | |
| John A. Rizzo; Richard Zeckhauser | |
| 发表日期 | 2005-06-27 |
| 出版年 | 2005 |
| 语种 | 英语 |
| 摘要 | Generic drug utilization has risen dramatically, from 19% of scrips in 1984 to 47% in 2001, thus bringing significant direct dollar savings. Generic drug use may also yield indirect savings if it lowers the average price of those brand-name drugs that are still purchased. Prior work indicates - and we confirm - that generic competition does not induce brand-name producers to lower prices. However, consumer choices between generic and brand-name drugs could affect the average price of those brand-name drugs that are purchased. We use nationally representative panel data on drug utilization and costs for the years 1996-2001 to examine how the share of an individual's prescriptions filled by generics affects his average out-of-pocket cost for brand-name drugs. Our principal finding is that a higher generic scrip share lowers average brand-name prices to consumers, presumably because consumers are more likely to substitute generics when the price gap is great. This effect is substantial: a 10% increase in the consumer's generic scrip share is associated with a 15.6% decline in the average price he pays for brand-name drugs. |
| 主题 | Health, Education, and Welfare ; Health ; Microeconomics ; Households and Firms ; Market Structure and Distribution |
| URL | https://www.nber.org/papers/w11431 |
| 来源智库 | National Bureau of Economic Research (United States) |
| 引用统计 | |
| 资源类型 | 智库出版物 |
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/569074 |
| 推荐引用方式 GB/T 7714 | John A. Rizzo,Richard Zeckhauser. Generic Scrip Share and the Price of Brand-Name Drugs: The Role of the Consumer. 2005. |
| 条目包含的文件 | ||||||
| 文件名称/大小 | 资源类型 | 版本类型 | 开放类型 | 使用许可 | ||
| w11431.pdf（273KB） | 智库出版物 | 限制开放 | CC BY-NC-SA | 浏览 | ||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
